RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

Nature Communications

Volumn 6, Issue , 2015, Pages

  Niederst, Matthew J ^a,b   Sequist, Lecia V ^a,b   Poirier, John T ^c   Mermel, Craig H ^a,d   Lockerman, Elizabeth L ^a,b   Garcia, Angel R ^a,b   Katayama, Ryohei ^a,b   Costa, Carlotta ^a,b   Ross, Kenneth N ^a,b   Moran, Teresa ^a,b,g   Howe, Emily ^a,b   Fulton, Linnea E ^a,b   Mulvey, Hillary E ^a,b   Bernardo, Lindsay A ^a,b   Mohamoud, Farhiya ^a,b   Miyoshi, Norikatsu ^a,b   VanderLaan, Paul A ^b   Costa, Daniel B ^b   Jänne, Pasi A ^e,f   Borger, Darrell R ^a,b   Ramaswamy, Sridhar ^a,b,d   Shioda, Toshi ^a,b   Iafrate, Anthony J ^a,b   Getz, Gad ^a,b,d   Rudin, Charles M ^c   Mino Kenudson, Mari ^a,b   Engelman, Jeffrey A ^a,b   more..

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROTEIN BCL 2; AFATINIB; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; BCL2 PROTEIN, HUMAN; BCL2L1 PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; NAVITOCLAX; PROTEIN BCL X; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; RETINOBLASTOMA PROTEIN; SULFONAMIDE;

CANCER; ENDOCRINOLOGY; GENE EXPRESSION; GENETIC MARKER; HISTOLOGY; INHIBITION; MUTATION; NEUROLOGY; PHENOTYPE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL LINE; CANCER RECURRENCE; CONTROLLED STUDY; EGFR GENE; FEMALE; GENE EXPRESSION; GENE LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; MALIGNANT TRANSFORMATION; MOUSE; MUTANT; NONHUMAN; PHENOTYPE; PROTEIN FAMILY; RB GENE; RECEPTOR GENE; SMALL CELL LUNG CANCER; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DEFICIENCY; DISEASE COURSE; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LUNG; LUNG NEOPLASMS; METABOLISM; MUTATION; PATHOLOGY; RECURRENT DISEASE; SIGNAL TRANSDUCTION; SMALL CELL LUNG CARCINOMA; TUMOR CELL LINE;

ADENOCARCINOMA; ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; BCL-X PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; ERLOTINIB HYDROCHLORIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECURRENCE; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; SMALL CELL LUNG CARCINOMA; SULFONAMIDES;

EID: 84924590266     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7377     Document Type: Article

References (37)

1. Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Engl. J. Med. 361, 947-957 (2009).
2. Mitsudomi, T. et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11, 121-128 (2010).
3. Maemondo, M. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. New Engl. J. Med. 362, 2380-2388 (2010).
4. Rosell, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13, 239-246 (2012).
5. Sequist, L. V. et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31, 3327-3334 (2013).
6. Ohashi, K., Maruvka, Y. E., Michor, F. & Pao, W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J. Clin. Oncol. 31, 1070-1080 (2013).
7. Sequist, L. V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011).
8. Zakowski, M. F., Ladanyi, M. & Kris, M. G. EGFR mutations in small-cell lung cancers in patients who have never smoked. New Engl. J. Med. 355, 213-215 (2006).
9. Morinaga, R. et al. Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. Lung Cancer 58, 411-413 (2007).
10. Okamoto, I. et al. EGFR mutation in gefitinib-responsive small-cell lung cancer. Ann. Oncol. 17, 1028-1029 (2006).
11. Fukui, T. et al. Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung. Cancer Sci. 98, 1714-1719 (2007).
12. Tatematsu, A. et al. Epidermal growth factor receptor mutations in small cell lung cancer. Clin. Cancer Res. 14, 6092-6096 (2008).
13. Yu, H. A. et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 19, 2240-2247 (2013).
14. Katayama, R. et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci. Transl. Med. 4, 120ra117 (2012).
15. Sasaki, T. et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 71, 6051-6060 (2011).
16. Crystal, A. S. et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346, 1480-1486 (2014).
17. Du, L. et al. MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs. J. Exp. Clin. Cancer Res. 29, 75 (2010).
18. Calbo, J. et al. A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell 19, 244-256 (2011).
19. Zhou, W. et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462, 1070-1074 (2009).
20. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
21. Shoemaker, A. R. et al. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin. Cancer Res. 14, 3268-3277 (2008).
22. Rudin, C. M. et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin. Cancer Res. 18, 3163-3169 (2012).
23. Gardner, E. E. et al. Rapamycin rescues ABT-737 efficacy in small cell lung cancer. Cancer Res. 74, 2846-2856 (2014).
24. Rudin, C. M. et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat. Genet. 44, 1111-1116 (2012).
25. Peifer, M. et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat. Genet. 44, 1104-1110 (2012).
26. van Meerbeeck, J. P., Fennell, D. A. & De Ruysscher, D. K. Small-cell lung cancer. Lancet 378, 1741-1755 (2011).
27. Miettinen, P. J. et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 376, 337-341 (1995).
28. Shiao, T. H. et al. Epidermal growth factor receptor mutations in small cell lung cancer: a brief report. J. Thorac. Oncol. 6, 195-198 (2011).
29. Byers, L. A. et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2, 798-811 (2012).
30. Sequist, L. V. et al. First-in-human evalulation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M. J. Clin. Oncol. 31(Suppl; abstr 2524) (2013).
31. Janjigian, Y. Y. et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J. Clin. Oncol. 29(Suppl; abstr 7525) (2011).
32. Yang, J. C. et al. Updated safety and efficacy from a phase I study of AZD9291 in patients (PTS) with EGFR-TKI-Resistant non-small cell lung cancer (NSCLC). EMSO Meet. Abstr. Ann. Oncol 25(Suppl 4): iv149 (2014).
33. Sequist, L. V. et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann. Oncol. 22, 2616-2624 (2011).
34. Corcoran, R. B. et al. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci. Signal. 3, ra84 (2010).
35. Morris, E. J. et al. E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8. Nature 455, 552-556 (2008).
36. Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043 (2007).
37. Garnett, M. J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575 (2012).